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The YBR159w gene encodes the major 3-ketoreductase
activity of the elongase system of enzymes required for
very long-chain fatty acid (VLCFA) synthesis. Mutants
lacking the YBR159w gene display many of the phenotypes that have previously been described for mutants
with defects in fatty acid elongation. These phenotypes
include reduced VLCFA synthesis, accumulation of high
levels of dihydrosphingosine and phytosphingosine, and
accumulation of medium-chain ceramides. In vitro elongation assays confirm that the ybr159⌬ mutant is deficient in the reduction of the 3-ketoacyl intermediates of
fatty acid elongation. The ybr159⌬ mutant also displays
reduced dehydration of the 3-OH acyl intermediates of
fatty acid elongation, suggesting that Ybr159p is required for the stability or function of the dehydratase
activity of the elongase system. Green fluorescent protein-tagged Ybr159p co-localizes and co-immunoprecipitates with other elongating enzymes, Elo3p and Tsc13p.
Whereas VLCFA synthesis is essential for viability, the
ybr159⌬ mutant cells are viable (albeit very slowly growing) and do synthesize some VLCFA. This suggested that
a functional ortholog of Ybr159p exists that is responsible for the residual 3-ketoreductase activity. By disrupting the orthologs of Ybr159w in the ybr159⌬ mutant we
found that the ybr159⌬ayr1⌬ double mutant was inviable, suggesting that Ayr1p is responsible for the residual
3-ketoreductase activity.

The distinct fatty acid compositions of different cellular
membranes highlight the importance of lipid structure and
composition for membrane function. The fatty acids are not
only structural components of membranes; they are also bioactive metabolites that regulate various cellular processes. Cytosolic fatty acid synthase catalyzes the de novo synthesis of
the majority of cellular fatty acids, which have 16 or 18
carbons. In contrast, the membrane-associated fatty acid
chain-elongating systems synthesize the very long-chain fatty
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acids (VLCFAs1; ⬎18 carbons). The VLCFAs confer unique
physical properties upon the lipids into which they are incorporated. Furthermore, different tissues contain structurally
distinct VLCFAs, suggesting that they confer tissue-specific
functions. For example, the VLCFAs in brain are predominantly saturated or monounsaturated with chain lengths of 24
or 26 carbons; those in the stomach, kidney, and brain are
␣-hydroxylated; and those in testes, epidermis, and retina are
polyunsaturated with chain lengths of up to 34 carbons.
Fatty acid elongation, beyond C16/C18 carbon atoms synthesized by fatty acid synthase in conjunction with Elo1p, is catalyzed by the microsomal “elongase” that consists of four distinct enzymatic reactions. In sequential order, these are a
condensation reaction between a CoA-esterified fatty acyl substrate and malonyl-CoA, a 3-ketoacyl-CoA reduction, a 3-hydroxyacyl-CoA dehydration, and a final enoyl-CoA reduction
(Fig. 1). Early biochemical studies suggested that the enzymatic activities reside in distinct proteins but that they may
associate into a complex that catalyzes fatty acid elongation. In
fact, the evidence suggests that there are multiple complexes
that elongate different FA substrates. For example, inhibition
studies indicated that different proteins are responsible for the
elongation of unsaturated and saturated fatty acids and for the
elongation of fatty acids of different chain lengths (1). The genetic
studies in yeast support these findings, since Elo2p and Elo3p are
homologous proteins believed to catalyze the same reaction but
with preferences for substrates of different chain lengths.
It has been hypothesized that the specificity of each elongation reaction is conferred through the selectivity of the first and
rate-limiting step, the condensation reaction. Investigators
working with Arabidopsis found that the FAE1 gene is required for VLCFA synthesis (2– 6). The FAE1 gene was predicted to encode a condensing enzyme (3-ketoacyl-CoA synthase) based on sequence homology with other condensing
enzymes (2). Biochemical characterization of the FAE1 gene
from both Arabidopsis and jojoba (7) supports the conclusion
that Fae1p is involved in VLCFA synthesis. Surprisingly, there
is no gene in Saccharomyces cerevisiae with significant homology to FAE1. On the other hand, the ELO homologs comprise a
gene family conserved from yeast to humans that are candidates for a novel class of condensing enzymes. Two lines of
experiments identified the S. cerevisiae ELO2 and ELO3 genes
as being required for VLCFA synthesis. Based on their homol-

1
The abbreviations used are: VLCFAs, very long-chain fatty acids;
LCB, long-chain base; ER, endoplasmic reticulum; FAMES, fatty acid
methyl esters; GCMS, gas chromatography mass spectrometry; SPT,
serine palmitoyltransferase; IPC, inositolphosphoceramide; PHS,
phytosphingosine; HA, hemagglutinin; GFP, green fluorescent protein.
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ogy to ELO1, a gene encoding a protein required to convert
myristate to palmitate (8, 9), the ELO2 and ELO3 genes were
determined to be required for VLCFA synthesis (10). We identified a role for the ELO2 and ELO3 genes in VLCFA synthesis
through the analysis of sphingolipid synthesis mutants (discussed below). Elo2p is involved in elongation of fatty acids up
to C22 or C24, whereas Elo3p has a broader substrate specificity and is essential for conversion of C24 to C26 (10).
The hypothesis that the specificity of elongation is conferred
by the condensing enzymes is further supported by the observation that heterologous expression in yeast of the plant Fae1p
condensing enzyme confers the ability to elongate C18:1 to
C20:1 and C22:1, although yeast does not normally elongate
monounsaturated fatty acids longer than C16 or C18 fatty
acids (11). Similarly, heterologous expression of the Caenorhabditis elegans ELO-like PEA1 gene in yeast confers the ability to elongate exogenously supplied polyunsaturated C18 fatty
acids, although yeast has only very limited endogenous capacity for synthesizing or elongating polyunsaturated fatty acids
(12, 13). We have previously shown that mutants defective in
the only yeast fatty acid desaturase, Ole1p, survive if supplemented with unsaturated C14:1⌬9 fatty acids that become
elongated to C16:1⌬11 by the Elo1p gene product (14).
In contrast to the Elo enzymes, which are believed to display
substrate specificity, it may be that the other elongating enzymes (two reductases and a dehydratase; see Fig. 1) are common components of the microsomal fatty acyl elongases that
function to lengthen all of the fatty acid elongase substrates.
We recently identified the TSC13 gene in a screen for temperature-sensitive (ts) mutants with defects in sphingolipid synthesis (15–17) and provided evidence that the TSC13 gene
encodes the enoyl reductase component of the microsomal elongase. Tsc13p was shown to coimmunoprecipitate with the presumptive condensing enzymes, Elo2p and Elo3p. Interestingly,
a growth state-dependent enrichment of Tsc13p to sites of
vacuole-nuclear envelope interaction was observed, but the
significance of this is unclear, and Elo2p and Elo3p do not
display this localization. TSC13 is essential, as is expected for
a gene encoding a nonredundant fatty acid-elongating activity.
In recent studies aimed at identifying other enzymatic components of the fatty acid elongase, we found that the YBR159w
gene is required for reconstituting heterologous (Fae1p- or
Pea1p-mediated) elongase activity in yeast. Here we report
analysis of the mutants lacking Ybr159p and demonstrate that
these mutant cells have many of the phenotypes that we have
previously described for the elo2⌬, elo3⌬, and tsc13-1 (elongasedefective) mutant cells. These phenotypes indicate that
Ybr159p is the major 3-ketoreductase activity required for endogenous VLCFA synthesis in yeast. We report that Ybr159p is
a nuclear/endoplasmic reticulum (ER)-localized protein that
associates in complexes with Elo3p and Tsc13p. Mutants that
are devoid of elongase activity (the elo2⌬elo3⌬ double mutant
or the tsc13⌬ mutant) are inviable, indicating that the VLCFAs
are essential. Although it grows poorly, the ybr159⌬ mutant is
viable, indicating that there is another gene that encodes a
3-ketoreductase activity that can function in fatty acid elongation. We provide evidence that the AYR1 gene, previously reported to encode 1-acyldihydroxyacetone-phosphate reductase
activity (18), is responsible for the residual fatty acid elongation activity.
EXPERIMENTAL PROCEDURES

Media, Strains, and Genetic Manipulations—Yeast media were prepared, and cells were grown according to standard procedures (19). The
majority of the yeast strains used in this study are listed in Table I. A
set of deletion mutants disrupted for putative oxidoreductases (Table
II) was purchased from Research Genetics.
To construct the ybr159::TRP1- and ybr159::URA3-disrupting al-
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FIG. 1. Pathway of fatty acid elongation. Each cycle of elongation
requires four successive reactions and lengthens the growing fatty acid
by two carbon units: condensation of malonyl-CoA with the acyl-CoA
substrate, reduction of the 3-ketoacyl-CoA, dehydration of the 3-hydroxy acyl-CoA, and reduction of the trans-2,3-acyl-CoA. Although the
intermediates and the product of the elongation cycle are shown as CoA
derivatives, this has not yet been experimentally confirmed.
leles, a SalI/XbaI-ended PCR fragment extending from 200 bp upstream of the start codon of YBR159w to 200 bp past the stop codon was
generated using primer 159F (SalI-ended 5⬘-ACAGCTGTCGACTATAGAGATAATTGTAGG-3⬘) and 159R (XbaI-ended 5⬘-AGAGCTCTAGATGATATTCTGGAAAAGCA-3⬘). The fragment was ligated between the
XhoI and XbaI sites of a Bluescript plasmid. The resulting plasmid was
digested with XhoI to remove a 779-bp fragment extending from codon
93 past the end of the YBR159w coding sequence. A SalI-ended TRP1
(or URA3) fragment, generated by PCR, was ligated into the XhoI site
at the deletion junction to generate the disrupting allele. The disrupting
allele was liberated from the plasmid by digestion with KpnI and NotI.
The ybr159::TRP1 elo3::URA3 double mutant was generated by transforming the KpnI/NotI-ended ybr159w::TRP1-disrupting fragment into
strain TDY 2054 (elo3::URA3) (16) and selecting tryptophan prototrophs. The replacement of the YBR159w allele by the ybr159::TRP1
allele was verified by PCR analysis. The ybr159w::TRP1 tsc13-1 double
mutant was generated by crossing a ybr159w::TRP1 haploid mutant
(TDY 1590, generated by disrupting YBR159w in TDY 2039) with TDY
2051a (tsc13-1) (16). The resulting diploid was sporulated, and following
tetrad dissection, the products of meiosis that were the ybr159w::TRP1
tsc13-1 double mutants were identified as tryptophan prototrophs that
were unable to grow at 37 °C.
The ypc1::kanMX-disrupting allele was generated by PCR using
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TABLE I
Strain list
Strain name

TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY
TDY

Genotype

Mat␣ ura3–52 leu2 trp1 lys2
Mata his4 ura3 trp1 leu2 elo2⬋URA3
Mata elo3⬋ura3 his4–619 ura3–52 trp1 leu2
Mat␣ ade2 ura3 trp1 leu2 lys2 elo2⬋TRP1 tsc13–1
Mat␣ ade2 ura3 trp1 leu2 lys2 elo3⬋TRP1 tsc13–1
Mat␣ ybr159⬋TRP1 ura3–52 trp1 leu2 lys2
Mata tsc13–1 ura3–52 trp1 leu2
Mat␣ ybr159⬋TRP1 tsc13–1 ura3–52 trp1 leu2 lys2
Mat␣ ybr159⬋TRP1 elo3⬋URA3 ura3–52 trp1 leu2 lys2
Mat␣ ura3–52 trp1 lys2 csg2⬋URA3
Mata ura3–52 trp1 leu2 lys2 his4 ybr159⬋TRP1 csg2⬋LEU2
Mata ura3–52 leu2 trp1 ade2 elo2⬋TRP1
Mat␣ ura3–52 leu2 trp1 lys2 ypc1⬋kanMX ydc1⬋URA3
Mat␣ ura3–52 leu2 trp1 lys2
Mat␣ ura3–52 leu2 trp1 lys2 ade2 ypc1⬋kanMX
Mat␣ ura3–52 leu2 trp1 lys2 ydc1⬋URA3
Mat␣ ura3–52 leu2 trp1 ade2 ypc1⬋kanMX ydc1⬋URA3
Mata ura3–52 leu2 trp1 lys2 elo2⬋TRP1
Mata ura3–52 leu2 trp1 ade2 elo2⬋TRP1 ypc1⬋kanMX
Mata ura3–52 leu2 trp1 elo2⬋TRP1 ydc1⬋URA3
Mata ura3–52 leu2 trp1 ade2 elo2⬋TRP ypc1⬋kanMX ydc1⬋URA3

2037
2053
2054
2057
2058
1590
2051a
1591
1593
2302
1592
5999
6000
6001
6002
6003
6004
6005
6006
6007
6008

TABLE II
Candidate genes responsible for residual 3-ketoreductase activity in the ybr159⌬ mutant
Gene

YMR226c
YIL124w/AYR1a
YIR036c
YKL055c/OAR1b
YDL114w
a
b

Homology to Ybr159p

Score ⫽ 171
Identities ⫽ 69/212
Score ⫽ 118
Identities ⫽ 44/183
Score ⫽ 108
Identities ⫽ 51/212
Score ⫽ 70
Identities ⫽ 25/106
Score ⫽ 91
Identities ⫽ 34/125

(32%), Positives ⫽ 102/212 (48%)
(24%), Positives ⫽ 85/183 (46%)
(24%), Positives ⫽ 92/212 (43%)
(23%), Positives ⫽ 53/106 (50%)
(27%), Positives ⫽ 60/125 (48%)

Ref. 18.
Ref. 34.

genomic DNA prepared from the Research Genetics strain harboring
the disruption and the EcoRI-ended YPC1F (5⬘-CCCGGGGATCCGCCGATTAGATCCGGCCC) and XbaI-ended YPC1R (5⬘-CCGGGCTCGAGCATGTCCCGAATTAGCTA) primers. Construction of the
ydc1::URA3-disrupting allele (kindly provided by the Obeid laboratory)
was described earlier (20). The YPC1 and YDC1 genes were sequentially disrupted in TDY 2037 to generate TDY 6000, which was crossed
to TDY 2053 (elo2⌬). This diploid was sporulated, and the tetrads were
dissected to generate the set of haploid strains (TDY 6001– 6008) having the various combinations of the ypc1::kanMX, ydc1::URA3, and
elo2⌬ mutations (Table I).
Construction of Ybr159p-GFP by Chromosomal Fusion—Chromosomal C-terminal GFP fusion to Ybr159p was performed by the short
flanking homology method (21). In brief, coding sequences for GFP and
the kanMX6 selection marker were amplified from template plasmid
pFA6a-GFPS65T-kanMX6 (provided by J. Hegemann, Heinrich-HeineUniversität, Düsseldorf, Germany) using hybrid primers homologous to
30 or 26 bp 5⬘ or 3⬘ of the template plasmid, respectively, and 50
nucleotides upstream or downstream of the chromosomal integration
sites, flanking the stop codon. The following primers were used (letters
in boldface type mark the vector sequences): YBR159 upstream primer,
5⬘-CTATCAGAATTAGAGCCTTAAAAAAAGCCGCAAGACAGGTTAAAAAGGAAGGAGCAGGTGCTGGTGCTGGTGCTGGAGCA-3⬘;
YBR159 downstream primer, 5⬘-ATATATATATATATATGTATTGTATAAAAACTATCTCGAGAACGATAATTATCGATGAATTCGAGCTCGTTTAAAC-3⬘. After transformation of the linear fragments into
FY1679 (MATa/␣ ura3–52/ura3–52 trp1⌬/TRP1 leu2⌬/LEU2 his3⌬/
HIS3 GAL2/GAL2) and selection of Geneticin-resistant colonies, cells
were sporulated, and haploid strains containing the GFP-tagged alleles
were selected. Growth tests in the presence of inhibitors of fatty acid
synthesis/elongation (cerulenin, soraphen A (22), and calcium) and at
elevated or reduced temperatures did not unveil any changes compared
with wild type, demonstrating that the GFP-tagged fusion allele of
YBR159w was fully functional.
The pYES-AT-159 Plasmid—An Arabidopsis thaliana expressed se-

quence tag (GenBankTM accession number AA10E08; kindly provided
by Prof. H. J. Bohnert, University of Arizona) derived from gene
F12A21.31 was used as template DNA for PCR amplification using
primers YAt159.for (5⬘-GCGGGTACCACCATGGAGATCTGCACTTAC3⬘) and YAt159.rev (5⬘-GCGGAGCTCTCATTCTTTCTTCATGGA-3⬘).
The amplified sequence was then restricted using KpnI and SacI (underlined in the forward and reverse primers, respectively), purified
using the Qiagen PCR purification kit, and ligated into the KpnI and
SacI sites of the pYES2 plasmid (Invitrogen).
Ceramide, Long-chain Base, and Fatty Acid Analyses—Ceramides
were extracted and analyzed by thin layer chromatography (TLC) as
previously described (23). Ceramides were purified by preparative silica
gel TLC and subjected to acid methanolysis, and the fatty acid methyl
esters (FAMEs) and long-chain bases (LCBs) were recovered as described earlier (23). LCBs were extracted, separated by TLC, and visualized using ninhydrin as described (15). Fatty acids were extracted,
and the FAMEs were prepared as previously described (16). Gas chromatography/mass spectrometry (GCMS) was performed using an HP
6890 Series GC system with a Supelcowax 10 column, coupled to an HP
5973 Mass Selective Detector.
Elongase Assays—Microsomes were prepared from the wild-type or
mutant cells as has been previously described (24). Total elongase
activity was measured in a volume of 200 l containing 50 mM Tris, pH
7.5, 1 mM MgCl2, 150 M Triton X-100, 1 mM NADPH, 1 mM NADH, 10
mM ␤-mercaptoethanol, 40 M palmitoyl-CoA, and 60 M [2-14C]malonyl-CoA (0.05 Ci/ml) at 37 °C. The reaction was initiated by the
addition of 0.3–1.0 mg of microsomal protein. Protein concentrations
were determined using the Bio-Rad protein assay reagent. For assays of
only the condensing activity, the NADPH and NADH were omitted. At
the indicated times, the reaction was terminated by adding 200 l of 5
M KOH, 10% MeOH and heating at 80 °C for 1 h. Following the addition
of 200 l of 10 N H2SO4, fatty acids were recovered by two 1.5-ml
extractions into hexane. The extracted fatty acids were resolved by
silica gel TLC using hexane/diethyl ether/acetic acid (30:70:1) as the
developing solvent. The radiolabeled fatty acids were detected and

Ybr159p Is the Major 3-Ketoreductase of Fatty Acid Elongation
quantified using a PhosphorImager SI (Amersham Biosciences).
Serine Palmitoyltransferase (SPT) Assays and Immunoblotting of
Lcb1p and Lcb2p—The SPT assays were preformed as previously described (24), except that 0.4 mg of microsomal protein and 75 M
palmitoyl-CoA were used. Each assay was conducted in quadruplicate,
and the average SPT activity is reported. The methods used for immunoblotting and for detection of Lcb1p and Lcb2p with the anti-Lcb1p
and anti-Lcb2p antibodies were also previously described (24).
Immunoprecipitation—Microsomes were prepared from strains containing Ybr159p-GFP and Tsc13p-MYC or containing Ybr159p-GFP,
Tsc13p-MYC, and Elo3p-HA. The microsomes were solubilized at 1
mg/ml with 2 mM sucrose monolaurate (Roche Molecular Biochemicals)
for 10 min, and the high speed (1 ⫻ 105 ⫻ g, 30 min) supernatant was
collected. The supernatant (150 l) was incubated with 25 l of the
precipitating antibody (0.5 mg/ml) coupled to Sepharose (from Babco,
Berkeley, CA) for 2 h. The precipitates were washed three times with
600 l of 50 mM HEPES, pH 7.5, and resuspended in 150 l of SDS
loading buffer, and a 10-l sample was subjected to 8% SDS-PAGE.
Following transfer of the separated proteins to nitrocellulose, the blots
were blocked in 0.1 M Tris, pH 7.5, 0.15 M NaCl, 0.1% Tween 20, 5% dry
milk. The Tsc13p-Myc was detected with horseradish peroxidase-conjugated monoclonal anti-Myc antibodies (from Invitrogen) at 1:5000.
Elo3p-HA was detected using horseradish peroxidase-conjugated monoclonal anti-HA antibodies (from Roche Molecular Biochemicals) at
1:1000. The bound antibodies were detected by the ECL Western blotting detection system (Amersham Biosciences).
Immunofluorescence and Fluorescence Microscopy—Immunostaining
of protein in yeast cells was performed as described (25) with the
following modifications. The cells harboring the Ybr159p-GFP chromosomal fusion were transformed with plasmids expressing Elo3p-HA,
Elo2p-HA, or Tsc13-MYC (the construction of these plasmids was described previously (16)). The cells were fixed with 4% methanol-free
formaldehyde in PBS for 2 h at room temperature. Cells were permeabilized in phosphate-buffered saline containing 0.1% Triton X-100,
0.05% saponin, 10 mM glycine, and 0.1% bovine serum albumin. Before
adding antibody, the digested cells were blocked by incubating in 10%
of bovine serum albumin for 30 min. For detecting Elo3p-HA or Elo2pHA, the cells were incubated with anti-HA rhodamine antibody (Roche
Molecular Biochemicals) at 2 g/ml in phosphate-buffered saline containing 1.0% bovine serum albumin, 0.1% Tween 20 for 2 h. For detecting Tsc13p-MYC, cells were incubated with a monoclonal anti-MYC
antibody (from Invitrogen; 1:200 dilution) followed by the Cy3-conjugated anti-mouse IgG secondary antibody (Sigma; 1:5000). Fluorescence microscopy was performed on an IX70 inverted fluorescence microscope (Olympus) equipped with a HiQ fluorescein filter set (for GFP,
excitation/emission was 460 – 490 nm/510 nm; for rhodamine and Cy3,
excitation/emission was 510 –550 nm/590 nm) and a Planapochromatic
⫻100 oil immersion objective lens and a 100-watt mercury lamp. Images were collected with a Princeton Instruments 5-MHz MicroMax
cooled CCD camera, a shutter and controller unit, and IPLab software
(version 3.5; Scanalytic Co.). Signals from the fluorescein isothiocyanate (Ybr159-GFP) and rhodamine and Cy3 fluorescence channels were
merged to unveil colocalization of signals.
RESULTS

Deletion of the YBR159w Gene Causes Slow Growth, Suppression of the Ca2⫹-sensitive Phenotype Associated with the
csg2⌬ Mutation, and Synthetic Lethality with the elo2⌬ Mutation—The Ybr159p protein was previously shown to be required
for C2 elongation of polyunsaturated fatty acids mediated by
heterologous expression of a C. elegans polyunsaturated fatty
acid-elongating activity F56H11.4 activity in S. cerevisiae (11).
The Ybr159p requirement for polyunsaturated fatty acid elongation along with its homology to oxidoreductases suggested
that it is the 3-ketoreductase activity of the endogenous elongase system in yeast. However, whereas the role of Ybr159p in
heterologous fatty acid elongation has been demonstrated,
whether or not it functions in endogenous elongation remained
to be determined. The role of Ybr159p in the synthesis of
endogenous VLCFAs is addressed in this study.
The ybr159⌬ mutant cells grow very slowly, especially upon
germination from spores (Fig. 2A) and when growing at elevated temperature (e.g. 37 °C) (11) (Fig. 2B). The presumptive
Arabidopsis thaliana homolog (F12A21.31; designated At-
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FIG. 2. The Ybr159⌬ mutation causes slow growth, synthetic
lethality with the elo2⌬ mutation, and suppression of the Ca2ⴙsensitive phenotype caused by the csg2⌬ mutation. A, a heterozygous ybr159::TRP1/YBR159⫹ diploid that had been transformed with a
p-YES-URA3 plasmid carrying the Arabidopsis thaliana YBR159w
homolog (F12A21.31) was sporulated and dissected on YPD agar plates.
The plates were incubated at 26 °C for 7 days and then photographed.
Subsequent analysis revealed which spores had the wild-type YBR159⫹
gene, which had the ybr159::TRP1-disrupted gene, and which harbored
the plasmid. The spore colonies from two representative tetrads are
shown. B, the growth phenotypes of the elongase single and double
mutants are shown. The indicated strains were grown in YPD medium
to an A600 of 0.1 and were diluted into the wells of a microtiter plate.
The cells were transferred to either YPD or SD plates, and the plates
were incubated at 26 °C for 3 days or 37 °C for 2 days. The
ybr159⌬elo2⌬ double mutant is missing because it is inviable. C, the
ybr159⌬ mutation suppresses the calcium sensitivity of the csg2⌬ mutant. The indicated strains were streaked onto YPD agar plates with or
without 50 mM CaCl2, and the plates were incubated at 26 °C for 3 days.
The ybr159⌬csg2⌬ double mutant is far less sensitive to calcium than
the csg2⌬ single mutant.

YBR159) of the S. cerevisiae YBR159w gene complemented the
deficiency in the heterologous microsomal elongation activity
associated with the ybr159⌬ mutation (11). Heterologous expression of the At-Ybr159p also complemented the slow growth
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phenotype of the ybr159⌬ mutant spores (Fig. 2A), demonstrating that the Arabidopsis gene also compensated for the endogenous (presumed VLCFA synthesis) defect that conferred slow
growth.
Mutations in the other known elongase genes (ELO2, ELO3,
and TSC13) suppress the Ca2⫹-sensitive phenotype of the
csg2⌬ mutation (16). The csg2⌬ mutant accumulates high levels of inositolphosphoceramide (IPC) due to failure to mannosylate IPC (17, 26). The accumulation of IPC confers Ca2⫹
sensitivity, and mutants that reduce IPC levels suppress the
Ca2⫹-sensitive phenotype (15). In wild-type yeast, all ceramides and sphingolipids contain C26-VLCFA; therefore, mutations that reduce fatty acid elongation reduce the levels of IPC
and thereby suppress the Ca2⫹ sensitivity conferred by the lack
of Csg2p. As would be expected if Ybr159p is required for
endogenous VLCFA synthesis, the ybr159⌬csg2⌬ double mutant was far less Ca2⫹-sensitive than the csg2⌬ single mutant
(Fig. 2C).
We also investigated whether combining the ybr159⌬ mutation with other elongase mutations would result in synthetic
growth phenotypes. For these studies, we crossed a ybr159⌬
mutant with a mutant harboring a second elongase mutation
(the elo2⌬, the elo3⌬, or the tsc13-1 mutation) to generate the
doubly heterozygous diploids. The products of meiosis were
analyzed following sporulation and tetrad dissection. We found
that the combination of the ybr159⌬ mutation with an elo2⌬
mutation was synthetically lethal, since all of the spores (from
16 tetrads) that could be deduced to have inherited both
mutations (the ybr159⌬elo2⌬ double mutant spores) failed to
germinate (data not shown). The ybr159⌬elo3⌬ and the
ybr159⌬tsc13-1 double mutants were both viable, but they
grew more slowly, especially at elevated temperatures, than
the single mutants (Fig. 2B).
The ybr159⌬ Mutant, Like Other Elongase Mutants, Accumulates Long-chain Bases and Medium-chain Ceramides—
In previous studies, we found that mutants with defects in
VLCFA synthesis accumulated very high levels of the free
LCBs, phytosphingosine (PHS) and dihydrosphingosine (16).
This phenotype is also observed for the ybr159⌬ mutant (Fig.
3A). The accumulation of high levels of free LCBs in the elongase mutants does not reflect reduced partitioning of the LCBs
into ceramides due to the VLCFA deficiency. Rather, the elongase mutants accumulate significant levels of medium-chain
ceramides containing PHS (discussed below), and thus the total
LCB levels (free LCBs and LCBs incorporated into ceramides
and sphingolipids) are increased in the mutants.
The elevated LCB pool suggested an increased rate of synthesis of the LCBs in the elongase mutants. Therefore, we
tested whether serine palmitoyltransferase (SPT), the committed and presumed rate-limiting enzyme of LCB synthesis, was
up-regulated in the elongase mutants. The abundance of the
Lcb1p and Lcb2p subunits of SPT was similar in microsomes
prepared from wild-type and elongase mutant cells (Fig. 3B).
We also measured SPT activity in microsomes prepared from
wild-type and elongase mutant microsomes and found no increase in the in vitro SPT activity for the elongase mutants
(Fig. 3C). These experiments indicate that the elevated LCBs
do not result from increased expression of the SPT enzyme. It
is possible that the reduced partitioning of palmitoyl-CoA (a
common substrate for SPT and the condensing enzyme of the
elongase system) into the elongase pathway results in enhanced LCB synthesis by providing higher substrate pools for
SPT. However, this is not likely, because a similar LCB-accumulating phenotype is reported for the lac1⌬lagl⌬ mutant
cells, but in this case the VLCFA levels are also elevated (27,
28) (see “Discussion”).

FIG. 3. Similar to the other elongase mutants, the ybr159⌬
mutant accumulates high levels of LCBs. A, LCBs were extracted
from 10 A600 units of the indicated cells, separated by TLC, and visualized by ninhydrin staining. The LCB standards sphingosine (SPH),
3-ketosphingosine (3-KS), dihydrosphingosine (DHS), and phytosphingosine (PHS) were spotted in lanes 1– 4 as indicated. The ninhydrinreactive species that migrate just above PHS and near the origin are
phosphatidylethanolamine (PE) and phosphatidylserine (PS) (see
standards, lanes 14 and 15). B, the elevated LCB levels in the elongase
mutants do not result from increased expression of the Lcb1p or Lcb2p
subunits of SPT. Ten g of microsomal proteins from the indicated
strains were resolved by SDS-PAGE electrophoresis, transferred to
nitrocellulose, and subjected to Western blot analysis using affinitypurified polyclonal anti-Lcb1p and anti-Lcb2p antibodies as previously
described (33). C, the in vitro SPT activity, measured using microsomes
from the indicated elongase mutants (33), is similar to the activity in
microsomes from the wild-type (wt) cells.

Whereas the ceramide (C-ceramide) in wild-type cells contains PHS and ␣-OH-C26 fatty acids, the elongase mutants
also accumulated significant levels of ceramides with shorter
chain fatty acids, and these fatty acids were also ␣-hydroxylated (16). These medium-chain (relatively hydrophilic) ceramides also accumulated in the ybr159⌬ mutant (Fig. 4A). The
presumptive medium-chain ceramides were eluted from the
TLC plate and subjected to acid methanolysis, and the resultant LCBs (by TLC) and FAMEs (by GCMS) were analyzed. The
ceramides were composed of PHS and ␣-OH-C16 fatty acids
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FIG. 4. The elongase mutants accumulate medium-chain ceramides: Synthesis of the medium-chain ceramides is not mediated by the Ypc1p and/or Ydc1p ceramidases. A, ceramides were
extracted from 10 A600 units of the indicated cells, separated by TLC,
and visualized by charring (23). Bovine ceramide type III (consisting of
sphingosine and C16-FA) and type IV (consisting of sphingosine and
␣-OH-C16-FA) standards run at the indicated positions. The major
ceramide in wild-type cells (C-ceramide) consists of PHS and ␣-OHC26-FA. The elongase mutants have reduced C-ceramide, and they
accumulate high levels of relatively hydrophilic ceramides that are
composed of PHS and ␣-OH-C16-FA (the medium-chain ceramides). B,
ceramides from 12.5 A600 units of the indicated strains were extracted
and analyzed by TLC. In this case, the ceramides were analyzed by UV
light after spraying the plates with 1% 8-anilino-1-napthalenesulfonic
acid. The deletion of YPC1 (lane 3), YDC1 (lane 4), or both YPC1 and
YDC1 (lane 9) did not prevent the medium-chain ceramides from accumulating in the elo2⌬ mutant. The medium-chain ceramides from the
bracketed region were eluted from the TLC plate and subjected to acid
methanolysis, and the FAMEs and LCBs that were produced were
recovered and analyzed.

(data not shown). A small amount of ceramide that was unhydroxylated on the C16 fatty acid (labeled B-ceramide in Fig. 4A)
was also present and migrated in the TLC between the type III
(unhydroxylated) and type IV (hydroxylated) bovine ceramide
standards. In addition, a novel species that migrated similarly
to the B-ceramide accumulated in the ybr159⌬ mutant (Fig.
4A). This species was found to be a 3-OH fatty acid (discussed
below).
These medium-chain ceramides might be synthesized by the
acyl-CoA-dependent ceramide synthase activity; however, in
wild-type cells, this enzyme appears to have high selectivity for
C26 fatty acyl CoA, despite the relatively high intracellular
level of C16 fatty acids. Alternatively, the medium-chain ceramides could arise from the reversal of a ceramidase activity,
possibly driven by the high LCB levels in the elongase mutants.
Two ceramidase-encoding genes, YPC1 and YDC1, with specificity toward PHS-containing and dihydrosphingosine-contain-
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ing ceramides respectively, have been identified in yeast
(20, 29). To determine whether the accumulation of the
medium-chain ceramides in the elongase mutants depends on
Ypc1p and/or Ydc1p, the ceramides from an elo2⌬ mutant,
an elo2⌬ypc1⌬ or an elo2⌬ydc1⌬ double mutant, or an
elo2⌬ypc1⌬ydc1⌬ triple mutant were compared. The mediumchain ceramide accumulation caused by the elo2⌬ mutation
was not blocked by eliminating the ceramidase genes (Fig. 4B).
The medium-chain ceramides from these strains were purified
and hydrolyzed by acid methanolysis, and again the LCB moiety of these ceramides was found to be PHS, and the fatty acid
moiety was found to be predominantly ␣-OH-C16 (data not
shown). Since deleting either YPC1 and/or YDC1 did not prevent the accumulation of the medium-chain ceramides, they
are most likely synthesized by the acyl-CoA-dependent ceramide synthase. This raises the question of why ceramide
synthase, which normally displays high selectivity for C26acyl-CoA, uses palmitoyl-CoA in the elongase mutants (see
“Discussion”).
These results show that the LCB- and medium-chain ceramide-accumulating phenotypes previously found to be characteristic of elongase mutants are also observed for the ybr159⌬
mutant and support a role for Ybr159p in endogenous VLCFA
synthesis. In addition, they demonstrate that the high levels of
LCBs in the mutants do not result from increased expression of
the Lcb1p and/or Lcb2p subunit of SPT. Finally, the mediumchain ceramides that accumulate in the elongase mutants do
not depend on the presence of the ceramidases, Ypc1p or Ydc1p.
In Vivo and in Vitro Assays of VLCFA Synthesis Confirm a
Deficiency in the ybr159⌬ Mutant—Fatty acids from wild-type,
ybr159⌬, ybr159⌬tsc13-1, and ybr159⌬elo3⌬ cells were extracted and analyzed by GCMS (see “Experimental Procedures”). As shown in Fig. 5, there was a significant reduction in
the levels of the C26 fatty acids in cells harboring the ybr159⌬
mutation. In addition, several fatty acid species were observed
in the mutants that were not present in wild-type cells, including ␣-OH-C16 fatty acid. As discussed above, the elongase
mutants synthesize ceramides that have C16 fatty acids,
whereas in wild-type cells the ceramides have exclusively C26
fatty acids. These medium-chain ceramides are substrates for
the ␣-hydroxylating enzyme, Scs7p, and thereby generate the
␣-OH-C16 fatty acids (16, 23). Thus, the accumulation of the
␣-OH-C16 fatty acids in the ybr159⌬ mutant reflects the accumulation of the medium-chain ceramides, a phenotype diagnostic of a VLCFA synthesis deficiency.
In addition to the ␣-OH-C16 fatty acids, the ybr159⌬ mutant
cells also accumulated 3-OH fatty acids of different chain
lengths (C16, C18, and C20). There are no known enzymes that
hydroxylate fatty acids or ceramides at C3; rather, these fatty
acids are presumed to be intermediates of the elongation pathway (Fig. 1). As mentioned above, the 3-OH fatty acids from the
ybr159⌬ mutant were also observed on the ceramide TLC
plates (see Fig. 4A). The accumulation of these 3-OH fatty acid
species suggests that the ybr159⌬ mutant is deficient in the
dehydratase activity as well as in the 3-ketoreductase activity
of the elongation system (discussed further below).
We previously assayed microsomes prepared from the
ybr159⌬ mutant for in vitro elongase activity (11). The first
step of the elongation cycle is the condensation of malonyl-CoA
with an acyl-CoA (e.g. palmitoyl-CoA) to form a 3-keto-acylCoA intermediate (Fig. 1). Omitting pyridine nucleotide from
the assay mix prevents the reduction of the 3-keto-acyl-CoA
intermediate and thereby allows the first step of elongation
(condensation) to be measured (Fig. 6, lane 1 of each panel). A
time course of the overall elongation was measured in the
presence of NADH/NADPH (Fig. 6, lanes 2– 4 of each panel).
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FIG. 5. The ybr159⌬ mutant cells are deficient in C26 fatty
acids and accumulate 2-OH-C16 and 3-OH-C16, -C18, and -C20
Fatty Acids. FAMEs were derived from the indicated strains and were
analyzed by GCMS. The profile spanning retention times from 9 to 21
min is shown. An internal C17 standard (retention time, 8.8 min),
added to the cells prior to the extraction, was used to normalize the
data. A small percentage of the fatty acids were not methylated (labeled
free fatty acids (FFA)).

Elongation intermediates did not accumulate during the elongation reactions catalyzed by the wild-type microsomes (Fig.
6a), which is consistent with previous studies of the rat microsomal elongating systems demonstrating that the condensation
reaction is rate-limiting (30). However, when microsomes prepared from the ybr159⌬ mutant were used in the assay, accumulation of the 3-keto-acyl and 3-hydroxyacyl intermediates
was observed (11) (Fig. 6b). This is consistent with the defect in
Ybr159p causing reduced activity of both the 3-ketoreductase
and the dehydratase activity of the elongase system.
We had also previously assayed in vitro elongation using
microsomes prepared from the tsc13-1 mutant. In this case,
accumulation of the trans-2,3-stearoyl and the 3-hydroxystearoyl intermediates was observed (16) (Fig. 6e). This is consistent with the defect in Tsc13p causing reduced activity of the
trans-2,3-enoyl-CoA reductase leading to accumulation of the
trans-2,3-stearoyl-CoA. Because the dehydratase step of elongation is reversible (31), accumulation of trans-2,3-stearoylCoA resulted in the observed accumulation of 3-hydroxystearoyl-CoA as well.

These previous studies were extended by comparing the elongase activity of microsomes prepared from mutants with various combinations of the elongase mutations (Fig. 6, f–i). These
experiments confirmed our previous finding that when
Ybr159p was missing, the 3-keto-acyl intermediate accumulated, consistent with Ybr159p being the major 3-ketoreductase
activity of the microsomal yeast fatty acid elongase system. In
addition, when Ybr159p was missing, the 3-OH-acyl intermediate of fatty acid elongation accumulated, indicating that the
dehydratase activity was also compromised in the absence of
Ybr159p. Significantly, when Tsc13p activity was deficient, the
3-OH-acyl intermediate accumulated in proportion to the
trans-2,3-acyl intermediate, as would be expected if it arose
from reversal of the dehydratase activity. On the other hand,
when Ybr159p was missing, there was a large increase in the
3-OH-acyl intermediate with no concomitant accumulation of
the trans-2,3-acyl intermediate. This indicates that when
Ybr159p is missing, the forward dehydratase activity is decreased to cause the 3-OH-acyl intermediate to accumulate,
whereas when Tsc13p is missing, the reverse dehydratase activity is increased to cause the 3-OH-acyl intermediate to
accumulate.
The in vitro elongase activity measured using the microsomes from the elo2⌬ (Fig. 6c) and elo3⌬ (Fig. 6d) single mutants appeared very similar to that with the wild-type microsomes, in that no intermediates accumulated. However, the
condensation activity in the elo2⌬ mutant was reduced about
3-fold (Fig. 6c), consistent with Elo2p being required for efficient condensation of palmitoyl-CoA with malonyl-CoA. The
reduced overall elongation in both the elo2⌬ and the ybr159⌬
mutants is also consistent with the observation that the
elo2⌬ybr159⌬ double mutant is inviable. Although the
elo3⌬ybr159⌬ double mutant accumulates both the 3-keto and
the 3-OH acyl intermediates, less 3-keto intermediate forms
than in the ybr159⌬ single mutant (Fig. 6f). This suggests that
the 3-keto intermediate that is formed by Elo2p (since Elo3p is
missing) is reduced more efficiently by an alternative 3-ketoreductase than the 3-keto intermediate formed by Elo3p, but this
requires further investigation. The ybr159⌬ mutation does not
prevent the accumulation of the trans-2,3-enoyl intermediate
in the ybr159⌬tsc13-1 double mutant; nor does the tsc13-1
mutation prevent the high 3-OH acyl intermediate associated
with the ybr159⌬ mutation from accumulating (Fig. 6g).
In summary, the accumulation of the 3-ketoacyl intermediate (in vitro) and the 3-OH acyl intermediate (both in vivo and
in vitro) indicate that both the 3-ketoreductase and the dehydratase activities are compromised in the ybr159⌬ mutant. The
accumulation of these intermediates is not blocked by the elo3⌬
mutation or by the tsc13-1 mutation. The synthetic lethal phenotype of the elo2⌬ybr159⌬ double mutant indicates that the
reduced overall elongation observed by either single mutant is
additive, making the double mutant unable to synthesize sufficient VLCFAs for viability.
The Ybr159p Protein Resides in the Endoplasmic Reticulum,
Co-localizes with Tsc13p and Elo3p, and Also Co-immunoprecipitates with Tsc13p and Elo3p—Tsc13p, Elo3p, and Elo2p all
displayed a perinuclear and peripheral staining consistent
with localization to the ER (16, 32). Furthermore, Tsc13p was
found to co-immunoprecipitate with Elo2p and with Elo3p,
indicating that the elongase proteins are organized in a complex. We next addressed whether Ybr159p co-localizes with and
associates with the other elongase proteins. Ybr159p has a
canonical dilysine ER retention motif, which along with its
homology to the oxidoreductases, was the criterion used to
identify it as a potential 3-ketoreductase of the elongase system
(11). In addition, all enzymes involved in fatty acid elongation
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FIG. 6. The ybr159⌬ mutant cells have normal condensation activity but are deficient in 3-ketoreductase and dehydratase activity.
Fatty acid elongation activity in microsomes prepared from the indicated strains was compared using C16-CoA as a substrate by measuring the
incorporation of radiolabeled malonyl-CoA into hexane-extractable fatty acids. The assays were conducted in the absence of NADPH/NADH for 5
min to measure condensation activity (lane 1 of each set). NADPH/NADH was included in the reactions measuring total elongation for 0.2 (lane
2), 1.0 (lane 3), or 5.0 (lane 4) min. The reactions were stopped at the indicated times, and the fatty acids were extracted and separated by TLC.
The positions of the 3-ketostearate (3-Keto), stearate (FA), trans-2,3-stearate (Trans-2,3), and 3-hydroxystearate (3-Hydroxy) intermediates were
determined by running the standards on the TLC plate and charring after exposure to PhosphorImager screens.

identified so far have very basic pI values (⬎9) and several
transmembrane domains, which is also characteristic for
Ybr159p.
To analyze subcellular localization, Ybr159p was C-terminally tagged with GFP by chromosomal fusion (see “Experimental Procedures”). The Ybr159p-GFP tagged protein was
functional because the strain grew normally, and the 2-OH and
3-OH fatty acids (diagnostic of an elongase defect) did not
accumulate. Indeed, localization studies of Ybr159p-GFP confirmed that it localizes to the nuclear/peripheral ER membrane
(Fig. 7A, panel a). The Ybr159-GFP protein co-localizes with
Elo3p-HA (Fig. 7A, panel b), Elo2p-HA (Fig. 7A, panel c), and
Tsc13p-Myc (Fig. 7A, panel d). The epitope-tagged proteins
were detected by immunofluorescence using either rhodamineconjugated anti-HA (for Elo3p and Elo2p) or Cy3-conjugated
anti-Myc (for Tsc13p-Myc) antibodies. Detailed microscopic
analyses of GFP-tagged Ybr159p unveiled exclusive ER localization throughout various growth phases and no enrichment
in the nuclear-vacuolar junctions (not shown). Thus, the physiological relevance of an enrichment of one component of the
microsomal fatty acid complex, Tsc13p, to nuclear-vacuolar
junctions remains obscure (16).
For the immunoprecipitation experiments, solubilized microsomes were prepared from cells that were co-expressing
Tsc13p-Myc and Ybr159p-GFP either with or without
Elo3p-HA (Fig. 7B). As we reported previously, the anti-HA
antibodies pulled down Tsc13p-Myc, and the anti-Myc antibodies pulled down Elo3p-HA when Tsc13p-Myc and Elo3p-HA
were co-expressed (Fig. 7B). These experiments also indicated
that Ybr159p-GFP associates with the Elo3p-HA/Tsc13p-Myccontaining complexes, since anti-GFP antibodies pulled down
Tsc13p-Myc and Elo3p-HA (Fig. 7B). Whether or not Ybr159p
co-immunoprecipitates with Elo2p has not yet been tested.
The Residual 3-Ketoreductase Activity in the Ybr159⌬ Mutant Is Likely to Depend on the AYR1 Gene Product—The results reported above indicate that the YBR159w gene encodes
the major 3-ketoreductase activity of the yeast elongase system
of enzymes. However, it cannot be the only gene that encodes
such an activity, because there is residual VLCFA synthesis in
the ybr159⌬ mutant (Fig. 5). Furthermore, other mutants that
fail to synthesize VLCFAs (the tsc13⌬ mutant and the
elo2⌬elo3⌬ double mutant) are inviable, whereas the ybr159⌬
mutant grows, albeit slowly. Therefore, we investigated

whether any of the genes most closely related to YBR159w was
likely to encode the residual 3-ketoreductase activity. We reasoned that disruption of the gene that encodes the residual
3-ketoreductase activity would be lethal in combination with
the ybr159⌬ mutation. There are several other putative oxidoreductase-encoding genes in yeast that display homologies
to the YBR159w gene (11) (Table II). We obtained the set
of haploid disruptant mutants in which each of these genes
had been replaced with the kanMX resistance marker (from
Research Genetics) and crossed them to the haploid
ybr159::URA3 mutant. For four of five candidates, Geneticinresistant uracil-prototrophic segregants of the heterozygous
diploid strains were recovered, indicating that the double mutants were viable. However, for the diploid that was heterozygous for the yil124w/ayr1::kanMX and the ybr159::URA3 mutations, no viable Geneticin-resistant uracil-prototrophic
meiotic segregants were recovered. Therefore, disruption of the
AYR1 gene was demonstrated to be synthetically lethal with
the ybr159⌬ mutation. In a previous study (18), spores harboring the ayr1⌬ mutation were found to be unable to germinate,
raising the possibility that the AYR1 gene was not disrupted in
the strain purchased from Research Genetics. However, we
confirmed the ayr1::kanMX disruption in this strain by PCR. In
our studies, the ayr1::kanMX single mutant spores germinated
as well as wild type; this phenomenon may be related to differences in the construction of the disrupting allele or in the
yeast strains.
To further investigate the possibility that Ayr1p catalyzes
3-ketoreductase activity in the ybr159⌬ mutant, we addressed
whether overexpression of Ayr1p would suppress the slow
growth phenotype of ybr159⌬ mutant spore colonies. However,
a high copy number (pRS424-TRP1-based) AYR1-containing
plasmid did not suppress the slow growth of ybr159⌬ mutant
spore colonies. The ayr1::kanMX mutant was also analyzed for
elongase phenotypes. However, the mutant did not accumulate
LCBs or medium-chain ceramides. Furthermore, in vivo fatty
acid analyses and in vitro elongase assays did not reveal any
evidence of a VLCFA synthesis defect in the ayr1⌬ mutant.
Finally, the ayr1⌬ mutation was not synthetically lethal with
the elo2⌬ or the elo3⌬ mutation. Therefore, although the synthetic lethality of the ayr1⌬ ybr159⌬ double mutant suggests
that Ayr1p provides the residual 3-ketoreductase activity in
the ybr159⌬ mutant, the lack of elongase phenotypes in the
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ayr1⌬ single mutant indicates that it is a minor activity. This
is consistent with Ybr159p being the major 3-ketoreductase of
the microsomal elongase.
DISCUSSION

The main conclusion from this study is that Ybr159p is the
major 3-ketoreductase activity of the endogenous yeast elongase system of enzymes required for VLCFA synthesis. This
conclusion is based on several observations. The ybr159⌬ mutant shares many of the phenotypes that are characteristic of
previously studied elongase mutants, including high levels of
LCBs and of medium-chain ceramides as well as low levels of
VLCFAs. The ybr159⌬ mutation is synthetically lethal in combination with an elo2⌬ mutation, and the ybr159⌬ mutation is
a suppressor of the csg2⌬ mutation. The in vitro elongation
assays reveal a defect in the 3-ketoreductase activity in the
mutant. These phenotypes, combined with the homology of
Ybr159p to other members of the oxidoreductases, support our
conclusion that this protein is a 3-ketoreductase.
Although Ybr159p is a major 3-ketoreductase responsible for
VLCFA synthesis, it is not the only enzyme in yeast responsible
for this activity. We provide evidence that Ayr1p is responsible
for the residual 3-ketoreductase activity in the ybr159⌬ mutant. Ayr1p was previously reported to be responsible for all of
the 1-acyldihydroxyacetone-phosphate reductase activity of
lipid particles as well as a significant fraction of this activity in
microsomes (18). That this enzyme apparently reduces both
1-acyldihydroxyacetone phosphate and 3-keto-acyl elongation
intermediates suggests that it is quite promiscuous. Whereas
our data suggest that Ayr1p has 3-ketoreductase activity, it is
possible that Ayr1p is essential in a ybr159⌬ mutant for another reason. For example, its role in phosphatidic acid biosynthesis through the dihydroxyacetone pathway (18) may alter
glycerophospholipid metabolism, and the combination of defects in VLCFA synthesis and glycerophospholipid metabolism
may result in the synthetic lethal phenotype of the ayr1⌬
ybr159⌬ double mutant. We note, however, that deletion of the
ayr1⌬ gene in other elongase mutants (elo2⌬ and elo3⌬) does
not confer synthetic lethality.
In addition to reduced 3-ketoreductase activity, the ybr159⌬
mutant is also deficient in the dehydratase activity that converts the 3-hydroxy intermediates formed during elongation to
the trans-2,3-enoyl intermediates. The basis of the dehydratase
deficiency in the ybr159⌬ mutant is not understood, but several
possibilities are suggested. For example, the Ybr159p enzyme
could be bifunctional and catalyze both the 3-keto reduction
and the subsequent dehydration reaction. This seems unlikely,
because the protein is homologous to characterized oxidoreductases over its entire length. Another possibility is that the
stability and or proper localization of the dehydratase depends
on the presence of Ybr159p. There are many examples in which
the loss of one component of a multienzyme complex results in
the instability of other components of the complex. A third
possibility is that the lack of Ybr159p, while not affecting the
stability of the dehydratase, precludes formation of the elongase complex. Clearly, the condensation step is not affected by

FIG. 7. Ybr159p-GFP resides in the nuclear/ER membrane; colocalizes with Elo3p-HA, Elo2p-HA, and Tsc13p-Myc; and coimmunoprecipitates with Elo3p-HA and Tsc13p-Myc. A, C-terminally tagged Ybr159p-GFP shows a typical ER localization pattern (i.e.
around the nucleus and cell periphery). Ybr159p-GFP co-localizes with
Elo3p, Elo2p, and Tsc13p. a, GFP fluorescence of Ybr159p-GFP; b, GFP
fluorescence of Ybr159p-GFP and immunofluorescence of Elo3p-HA
with rhodamine-conjugated anti-HA; c, GFP fluorescence of Ybr159pGFP and immunofluorescence of Elo2p-HA with rhodamine-conjugated
anti-HA; d, GFP fluorescence of Ybr159p-GFP and immunofluorescence

of Tsc13p-Myc with Cy3-conjugated anti-Myc. B, anti-GFP antibodies
coimmunoprecipitate Elo3p-HA and Tsc13p-Myc with Ybr159p-GFP.
Microsomes were prepared from cells containing Ybr159-GFP with
Tsc13p-Myc alone (on left) or with Tsc13p-Myc and Elo3p-HA. The
microsomes were solubilized, and the 100,000 ⫻ g supernatant was
used for immunoprecipitation with Sephadex beads (lane 1) or Sephadex beads conjugated to anti-GFP (lane 2), anti-HA (lane 3), or antiMyc (lane 4) antibodies. The immunoprecipitated proteins were separated by SDS-PAGE and analyzed by immunoblotting with horseradish
peroxidase-conjugated anti-Myc or anti-HA antibodies as indicated.
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the absence of Ybr159p, since the 3-keto intermediate is formed
in the ybr159⌬ mutant. Future studies will address whether
Elo3p (and Elo2p) still associate with Tsc13p in the ybr159⌬
mutant. Attempts to identify the putative dehydratase by copurification with the other elongase components are also in
progress.
We reported previously that the tsc13-1 mutant, deficient in
the trans-2,3-enoyl reductase activity of the elongase, also accumulates the 3-OH-acyl intermediate. We assumed that the
lethality of the tsc13⌬ mutant resulted from the failure to
synthesize VLCFAs. The essentiality of the VLCFAs is also
indicated by the synthetic lethality of the elo2⌬elo3⌬ double
mutant. However, in the case of the tsc13⌬ mutant, it remained
a possibility that the lethality was actually caused by the
accumulation of the 3-OH acyl intermediate. The observation
that the ybr159⌬ mutant, which accumulates high levels of the
3-OH acyl elongation intermediates, is viable (albeit slowly
growing) strengthens our conclusion that the tsc13⌬ mutant is
lethal due to failure to synthesize VLCFAs.
The elongase mutants accumulate very high levels of free
LCBs that do not result from reduced partitioning into ceramides. These observations indicate that either LCB synthesis
is up-regulated or LCB degradation is down-regulated in the
mutants. We tested whether SPT levels were elevated in the
mutants and found no change in the abundance of the Lcb1p or
Lcb2p proteins, or in the in vitro SPT activity. In the case of the
elongase mutants, reduced partitioning of palmitoyl-CoA into
the VLCFAs might increase flux into the LCB synthesis pathway. However, the lag1⌬lac1⌬ mutant, which is defective in
acyl-CoA-dependent ceramide synthase, also displays elevated
free LCBs, but this mutant also has increased levels of VLCFAs
as well. That is, both LCB synthesis and VLCFA synthesis
pathways appear to be up-regulated in this mutant (27, 28).
Thus, it seems more likely that the synthesis of the LCBs and
the VLCFAs (possibly coordinately regulated by the availability of palmitoyl-CoA in the ER) are subject to regulation by a
downstream product of the sphingolipid pathway. This is most
likely either ceramide or IPC, because the csg2⌬ mutant, which
is defective in mannosylation of IPC, does not accumulate
LCBs or high VLCFAs.2 Clearly, it will be important to investigate how this regulation is achieved.
The elongase mutants also synthesize medium-chain ceramides that do not arise from reversal of the Ypc1p and/or Ydc1p
ceramidase activities. Thus, we propose that the medium-chain
ceramides are synthesized by the acyl-CoA-dependent ceramide synthase. The accumulation of the medium-chain ceramides might simply result from reduced C26 synthesis, but
again this seems unlikely because the medium-chain ceramides also accumulate in the lac1⌬lag1⌬ mutant, which synthesizes elevated levels of C26 fatty acids (27). This raises the
interesting possibility that the elongase complex may associate
with ceramide synthase and that the C26-acyl-CoA may be
channeled from the elongase to ceramide synthase. The studies
of the lac1⌬lag1⌬ mutant clearly implicate these genes in the
synthesis of C26 ceramides (27, 28), but it is possible that they
do not encode the ceramide synthase activity per se. For example, it could be (as suggested by Conzelmann and co-workers
(27)) that Lag1p and Lac1p are required for conferring speci2
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ficity for the C26-CoA substrate to ceramide synthase. Perhaps
the Lag1p/Lac1p coupling of the elongase to ceramide synthase
is eliminated in either the elongase mutants or in the
lac1⌬lag1⌬ mutant. This might result in loss of discrimination
for C26-CoA by ceramide synthase, which would account for
the medium-chain ceramides. Future experiments will be
aimed at understanding the origin of the high levels of LCBs
and of the medium-chain ceramides in the elongase and
lag1⌬lac1⌬ mutants.
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